JP2022547604A - 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用 - Google Patents

過度の眠気の治療のためのオレキシン２受容体アゴニストの使用 Download PDF

Info

Publication number
JP2022547604A
JP2022547604A JP2022516271A JP2022516271A JP2022547604A JP 2022547604 A JP2022547604 A JP 2022547604A JP 2022516271 A JP2022516271 A JP 2022516271A JP 2022516271 A JP2022516271 A JP 2022516271A JP 2022547604 A JP2022547604 A JP 2022547604A
Authority
JP
Japan
Prior art keywords
compound
subject
effective amount
methyl
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022516271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547604A5 (https=
Inventor
ハートマン、デボラ
エヴァンス、レベッカ
ファエッセル、ヘレーネ
ルーベンス、ロバート
慎一郎 田中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2022547604A publication Critical patent/JP2022547604A/ja
Publication of JP2022547604A5 publication Critical patent/JP2022547604A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022516271A 2019-09-13 2020-09-12 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用 Pending JP2022547604A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900310P 2019-09-13 2019-09-13
US62/900,310 2019-09-13
US202063031687P 2020-05-29 2020-05-29
US63/031,687 2020-05-29
PCT/IB2020/058482 WO2021048821A1 (en) 2019-09-13 2020-09-12 Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness

Publications (2)

Publication Number Publication Date
JP2022547604A true JP2022547604A (ja) 2022-11-14
JP2022547604A5 JP2022547604A5 (https=) 2023-09-20

Family

ID=72521681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516271A Pending JP2022547604A (ja) 2019-09-13 2020-09-12 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用

Country Status (11)

Country Link
US (1) US20220331303A1 (https=)
EP (1) EP4028003A1 (https=)
JP (1) JP2022547604A (https=)
KR (1) KR20220062361A (https=)
CN (1) CN114555083A (https=)
AU (1) AU2020347578A1 (https=)
BR (1) BR112022004576A2 (https=)
CA (1) CA3154320A1 (https=)
CO (1) CO2022004589A2 (https=)
MX (1) MX2022003017A (https=)
WO (1) WO2021048821A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
MX2022008392A (es) 2020-01-10 2022-08-08 Takeda Pharmaceuticals Co Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AR130709A1 (es) 2022-10-07 2025-01-08 Kissei Pharmaceutical Compuesto de ciclopentano
TW202502342A (zh) * 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
CA3154321A1 (en) * 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Tak-925 for use in treating narcolepsy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019504098A (ja) * 2016-02-04 2019-02-14 武田薬品工業株式会社 置換ピペリジン化合物およびその用途

Also Published As

Publication number Publication date
KR20220062361A (ko) 2022-05-16
AU2020347578A1 (en) 2022-04-14
WO2021048821A8 (en) 2021-11-04
BR112022004576A2 (pt) 2022-06-14
EP4028003A1 (en) 2022-07-20
US20220331303A1 (en) 2022-10-20
WO2021048821A1 (en) 2021-03-18
MX2022003017A (es) 2022-06-14
CN114555083A (zh) 2022-05-27
CA3154320A1 (en) 2021-03-18
CO2022004589A2 (es) 2022-04-29

Similar Documents

Publication Publication Date Title
JP2022547604A (ja) 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用
JP2022547711A (ja) ナルコレプシーの治療に使用するためのｔａｋ－９２５
TWI298254B (en) Use of optically pure (s,s) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome
US9700548B2 (en) Antihistamines combined with dietary supplements for improved health
AU2018260666A1 (en) Methods and compositions for treating sleep apnea
WO2006023703A2 (en) Method for treating sleep related breathing disorders
JP2025510294A (ja) 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
TW202339764A (zh) 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
JP2022547604A5 (https=)
KR20250005183A (ko) 사회적/정서적 고립 또는 분리의 치료를 위한 5-메톡시-n,n-디메틸트립타민
IL322430A (en) 5-MEO-DMT for use in the treatment of postpartum depression
TW202228666A (zh) 使用ghb之治療方法
TW202302100A (zh) 食慾激素２受體促效劑於治療食慾激素介導之疾病或病症之用途
WO2022208478A1 (en) Use of an orexin 2 receptor agonist for post operation recovery
JP6031722B2 (ja) 女性の排尿障害の治療剤
US20240284941A1 (en) Antihistamines combined with dietary supplements for improved health
Sorrentino et al. An overview of the current management and emerging therapies of Multiple system atrophy
EP4376954A1 (en) Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN118843459A (zh) 用于治疗抑郁症的组合物和方法
Currow Pharmacological approaches to
EP2269600A1 (en) Treatment of sleep disorders using eplivanserin in COPD patients
Juncos Perioperative management of patients with Parkinson’s disease
US20120172390A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250128